The TG Therapeutics logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11857

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for TG-1101 and TGR-1202 and may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at  www.tgtherapeutics.com . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

TGTX - G
CONTACT: Jenna Bosco         Director - Investor Relations         TG Therapeutics, Inc.         Telephone: 212.554.4484         Email: ir@tgtxinc.com

TG Therapeutics Logo

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

Lockheed Martin, TG Therapeutics, HD Supply: 'Mad Money' Lightning Round

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Biotech Needs a Shot in the Arm